These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 20567960

  • 1. [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
    Schmidt S.
    Nervenarzt; 2010 Oct; 81(10):1231-41. PubMed ID: 20567960
    [Abstract] [Full Text] [Related]

  • 2. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ, CLARITY Study Group.
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [Abstract] [Full Text] [Related]

  • 3. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
    Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
    [Abstract] [Full Text] [Related]

  • 4. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA, Katz J, Robertson D, Hayward B, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ.
    Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
    [Abstract] [Full Text] [Related]

  • 5. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T, Torkildsen Ø, Myhr KM.
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [Abstract] [Full Text] [Related]

  • 6. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
    Rammohan K, Coyle PK, Sylvester E, Galazka A, Dangond F, Grosso M, Leist TP.
    Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
    [Abstract] [Full Text] [Related]

  • 7. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M.
    Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
    [Abstract] [Full Text] [Related]

  • 8. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC.
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P.
    Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
    [Abstract] [Full Text] [Related]

  • 10. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul 29; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract] [Full Text] [Related]

  • 11. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.
    Mult Scler Relat Disord; 2019 Apr 29; 29():168-174. PubMed ID: 30885375
    [Abstract] [Full Text] [Related]

  • 12. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
    [Abstract] [Full Text] [Related]

  • 13. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
    Giovannoni G.
    Neurotherapeutics; 2017 Oct 04; 14(4):874-887. PubMed ID: 29168160
    [Abstract] [Full Text] [Related]

  • 14. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun 04; 9(3):198. PubMed ID: 19527090
    [No Abstract] [Full Text] [Related]

  • 15. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
    Terranova N, Hicking C, Dangond F, Munafo A.
    Clin Pharmacokinet; 2019 Mar 04; 58(3):325-333. PubMed ID: 29992396
    [Abstract] [Full Text] [Related]

  • 16. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb 04; 56(2):21-24. PubMed ID: 29449328
    [Abstract] [Full Text] [Related]

  • 17. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
    Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC.
    Drug Des Devel Ther; 2010 Jul 21; 4():117-26. PubMed ID: 20689698
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul 21; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B, Guerreiro R, Costa J, Miguel LS.
    J Med Econ; 2020 May 21; 23(5):484-491. PubMed ID: 31951777
    [Abstract] [Full Text] [Related]

  • 20. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
    Gorrod HB, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL.
    Value Health; 2019 Jul 21; 22(7):772-776. PubMed ID: 31277823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.